Di Giacomo, AM, Schenker, M, Medioni, J, Mandziuk, S, Majem, M, Gravis, G, Cornfeld, M, Ranganathan, S, Lou, S, Csoszi, T. A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203). ESMO Open. 2024; 9(3)DOI:10.1016/j.esmoop.2024.102387. PMID:38401247. IF:8.300(Q1/2D).

Grünwald, V, Powles, T, Eto, M, Kopyltsov, E, Rha, SY, Porta, C, Motzer, R, Hutson, TE, Méndez-Vidal, MJ, Hong, SH, Winquist, E, Goh, JC, Maroto, P, Buchler, T, Takagi, T, Burgents, JE, Perini, R, He, CX, Okpara, CE, McKenzie, J, Choueiri, TK. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023). Frontiers in Oncology. 2024; 13DOI:10.3389/fonc.2023.1343027. PMID:38495081. IF:3.300(Q2/4D).

Day, E, Gavira, J, Tapia, JC, Anguera, G, Maroto, P. What About Variant Histologies in Bladder Cancer?. European Urology Focus. 2024; 10(2)DOI:10.1016/j.euf.2024.05.015. PMID:38849276. IF:5.600(Q1/1D).

Arqueros, C, Gallardo, A, Vidal, S, Osuna-Gómez, R, Tibau, A, Bell, OL, Cajal, T, Lerma, E, Lobato-Delgado, B, Salazar, J, Barnadas, A. Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2024; 25(5)DOI:10.3390/ijms25052627. PMID:38473874. IF:4.900(Q1/3D).

Angelo, ED, Espinosa, I, Wang, AH, Kingsley, L, Nasr, S, Zdravkovic, S, Howitt, B, Prat, J. A Clinicopathologic and Immunohistochemical Analysis of 46 Uterine Mesenchymal Tumors Including Conventional Adenosarcomas, Atypical Uterine Polyps and Other Related Sarcomas. LABORATORY INVESTIGATION. 2024; 104(3)DOI:. PMID:. IF:4.200(Q1/1D).

Espinosa, I, D'Angelo, E, Gallardo, A, Lee, CH, Koebel, M, Prat, J. Loss of Expression of ARID1a and PBRM1 Proteins Is Associated with Poor Prognosis in Mullerian Adenosarcomas. LABORATORY INVESTIGATION. 2024; 104(3)DOI:. PMID:. IF:4.200(Q1/1D).